NMDA NR2A Subunit (Tyr1325) Antibody

The ion channels activated by glutamate that are sensitive to N-methyl-D-aspartate (NMDA) are designated NMDA receptors (NMDAR) . The NMDAR plays an essential role in memory, neuronal development and it has also been implicated in several disorders of the central nervous system including Alzheimer’s, epilepsy and ischemic neuronal cell death (Grosshans et al., 2002; Wenthold et al., 2003; Carroll and Zukin, 2002) . The NMDA receptor is also one of the principal molecular targets for alcohol in the CNS (Lovinger et al., 1989; Alvestad et al., 2003; Snell et al., 1996) . Channels with physiological characteristics are produced when the NR1 subunit is combined with one or more of the NMDAR2 (NR2 A-D) subunits (Ishii et al., 1993) . Recently, phosphorylation of Tyrosine 1325 of the NR2A subunit has been shown to be increased in human brain tissue sections from HIV-infected individuals with encephalitis (King et al., 2010) . In addition, Tyr-1325 phosphorylation has been linked with depression-related behavior (Taniguchi et al., 2009) .

EPND antibody, FESD antibody, GluN2A antibody, Glutamate [NMDA] receptor subunit epsilon-1 antibody, Glutamate receptor antibody, Glutamate receptor ionotropic N methyl D aspartate 2A antibody, GRIN 2A antibody, GRIN2A antibody, hNR2A antibody, LKS antibody, N methyl D aspartate receptor channel subunit epsilon 1 antibody, N Methyl D Aspartate Receptor Subtype 2A antibody, N methyl D aspartate receptor subunit 2A antibody, N-methyl D-aspartate receptor subtype 2A antibody, NMDA receptor subtype 2A antibody, NMDAR 2A antibody, NMDAR2A antibody, NMDE1_HUMAN antibody, NR2A antibody, OTTHUMP00000160135 antibody, OTTHUMP00000174531 antibody

Synthetic phospho-peptide corresponding to amino acid residues surrounding Tyr1325 of the rat NMDA receptor, conjugated to keyhole limpet hemocyanin (KLH) .

Specific for endogenous levels of the ~180k NMDAR NR2A-subunit protein phosphorylated at Tyr1325 in Western blots. Immunolabeling is completely eliminated by treatment with λ-phosphatase.